Stocks in play: Oncolytics Biotech Inc
Announced the poster presentation of positive, updated results from the Phase 1/2 GOBLET study evaluating ... Oncolytics Biotech Inc has announced positive results from its Phase 1/2 GOBLET study, which tested pelareorep-based combination therapy in patients with pancreatic ductal adenocarcinoma (PDAC). The study was presented at the European Society for Medical Oncology meeting (ESMO 2023) in Madrid, Spain. Highlights include a 25% increase in outcomes from the previous study and T-cell expansion data indicating an important proof-of-concept. Shares of Oncolytic Biotech are unchanged at $2.14.
发表 : 2年前 经过 Baystreet 在 Finance Tech
Announced the poster presentation of positive, updated results from the Phase 1/2 GOBLET study evaluating pelareorep-based combination therapy in patients with pancreatic ductal adenocarcinoma (PDAC) at the European Society for Medical Oncology meeting (ESMO 2023), taking place in Madrid, Spain. Highlights include; 7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by = 25%; alsoT-cell expansion data correlate with tumor response, providing important proof-of-concept. Oncolytics Biotech Inc shares T.ONC are trading unchanged at $2.14.
• None The Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC Firm
• None Canada’s Gold Sector Gaining Boosts from Several Promising Quebec Projects and Mines
• None Decoding the Lithium Rush: From Oil Giants to Automakers
• None Time Bomb Ticking as Surplus in Carbon Offset Credits on Path Towards Huge Shortage
• None Breakthroughs in Pancreatic Cancer Treatment: How FDA Designations are Changing the Game
话题: Markets, Biotech